Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Why Bapcor, Carsales, Mesoblast, & Santos shares are racing higher
Coronavirus News
Mesoblast share price rockets 30% higher on COVID-19 treatment hopes
⏸️ Investing
This ASX biotech share is joining the race for a COVID-19 cure. Could it rejoin the ASX 200 too?
Share Fallers
Why James Hardie, LNG, Mesoblast, & Westpac shares are tumbling lower
Healthcare Shares
2 ASX biotech shares that could be the next CSL
Healthcare Shares
ASX biotech share surges 20% higher on COVID-19 drug trial
Share Gainers
Why Afterpay, Mesoblast, Netwealth, & oOh!Media are surging higher
Share Gainers
Why DEXUS, Magellan, Mesoblast, & SEEK are surging higher
Share Gainers
Why Mesoblast, Redbubble, Santos, & Scentre shares are surging higher
Share Gainers
Mesoblast share price jumps 12% on FDA update
Share Fallers
Why Caltex, Mesoblast, PointsBet, & Webjet are crashing lower today
Share Gainers
Why Afterpay, Jumbo, Mesoblast, & Orora shares are surging higher
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
